Lunai Bioworks secures first defense contract and establishes Pathfinder Consortium

Lunai Bioworks announced a multi-year revenue-generating defense collaboration with the U.S. government for AI-enabled chemical threat assessment and established partnerships with leading research institutions. The company is positioning its Augusta platform to align with national security priorities while advancing precision neurology applications in epilepsy, Parkinson's, and Alzheimer's disease.